scholarly journals The Epidemiology of Panic Attacks, Panic Disorder, and Agoraphobia in the National Comorbidity Survey Replication

2006 ◽  
Vol 63 (4) ◽  
pp. 415 ◽  
Author(s):  
Ronald C. Kessler ◽  
Wai Tat Chiu ◽  
Robert Jin ◽  
Ayelet Meron Ruscio ◽  
Katherine Shear ◽  
...  
2011 ◽  
Vol 20 (2) ◽  
pp. 105-115 ◽  
Author(s):  
Jennifer Greif Green ◽  
Shelli Avenevoli ◽  
Matthew Finkelman ◽  
Michael J. Gruber ◽  
Ronald C. Kessler ◽  
...  

2010 ◽  
Vol 67 (2) ◽  
pp. 113 ◽  
Author(s):  
Jennifer Greif Green ◽  
Katie A. McLaughlin ◽  
Patricia A. Berglund ◽  
Michael J. Gruber ◽  
Nancy A. Sampson ◽  
...  

Author(s):  
Ronald C. Kessler ◽  
Shelli Avenevoli ◽  
E. Jane Costello ◽  
Jennifer Greif Green ◽  
Michael J. Gruber ◽  
...  

2006 ◽  
Vol 63 (6) ◽  
pp. 669 ◽  
Author(s):  
Ronald C. Kessler ◽  
Emil F. Coccaro ◽  
Maurizio Fava ◽  
Savina Jaeger ◽  
Robert Jin ◽  
...  

1989 ◽  
Vol 3 (2) ◽  
pp. 107-115 ◽  
Author(s):  
Janet Woodruff Borden ◽  
George A. Clum ◽  
Susan E. Broyles
Keyword(s):  

2005 ◽  
Vol 25 (6) ◽  
pp. 761-789 ◽  
Author(s):  
Michael J. Zvolensky ◽  
Matthew T. Feldner ◽  
Ellen W. Leen-Feldner ◽  
Alison C. McLeish

2000 ◽  
Vol 58 (4) ◽  
pp. 1025-1029 ◽  
Author(s):  
ALEXANDRE MARTINS VALENÇA ◽  
ANTONIO EGIDIO NARDI ◽  
ISABELLA NASCIMENTO ◽  
MARCO A. MEZZASALMA ◽  
FABIANA L. LOPES ◽  
...  

OBJECTIVE: To assess the effectiveness of clonazepam, in a fixed dose (2 mg/day), compared with placebo in the treatment of panic disorder patients. METHOD: 24 panic disorder patients with agoraphobia were randomly selected. The diagnosis was obtained using the structured clinical interview for DSM-IV . All twenty-four subjects were randomly assigned to either treatment with clonazepam (2 mg/day) or placebo, during 6 weeks. Efficacy assessments included: change from baseline in the number of panic attacks; CGI scores for panic disorder; Hamilton rating scale for anxiety; and panic associated symptoms scale. RESULTS: At the therapeutic endpoint, only one of 9 placebo patients (11.1%) were free of panic attacks, compared with 8 of 13 (61.5%) clonazepam patients (Fisher exact test; p=0,031). CONCLUSION: the results provide evidence for the efficacy of clonazepam in panic disorder patients.


2021 ◽  
Vol 9 (T3) ◽  
pp. 237-239
Author(s):  
Muhammad Surya Husada ◽  
Mustafa M. Amin ◽  
Munawir Saragih

Background: COVID-19 is a newly emerging infectious disease which is found to be caused by SARS-2. COVID-19 pandemic has spread worldwide causing a rapidly increasing number of mental disorders cases, primarily anxiety disorder. Since majority of panic disorder patients are present with great anxiety in response to their physical or respiratory symptoms, support and encouragement from psychiatrist or therapist are fundamental to alleviate the severity of the symptoms. Case Report: We reported a case of COVID-19 induced panic disorder in a woman, 52 years old, batak tribe who started to experience multiple panic attacks since one of her family members was confirmed to be Covid-10 positive. Conclusion: In general, panic disorder is a common diagnosis, but this case appeared to be interesting as it is induced by COVID-19 pandemic. As in this case, the individual who experienced multiple panic attack is not even a COVID-19 patient but has one of her family member affected by the virus. A wide body of evidence has shown that this pandemic massively contributes to worsening of psychosocial burden in nationwide.


Sign in / Sign up

Export Citation Format

Share Document